INO Inovio $10.28 +0.66(+6.86%) Broadwind initiated with a Buy at Johnson Rice 16:23 BWEN Johnson Rice analyst… Penn National initiated with a Buy at Rosenblatt 16:13 PENN Roth bumps up Applied Genetic price target to $26 after earnings, XLRP updates
Uh, uh, uh, uh Day and night gummybearadvisors does it right I toss and turn, I keep stressing my mind, mind (what grotto, what grotto) I look for peace but see I don't attain (what, what) that fence post was in cement. What I need for keeps this silly game we play, play me vs the land trust Now look at this (what, what) it's UP Up. Madness to magnet keeps attracting me, me stocks that grow like trees (what, what) I try to run but see I'm not that fast (what, what) I think I'm first but surely finish last, last 'Cause day and night The lonely stoner seems to free his mind at night He's all alone somethings will never change watching the Raptors play The lonely loner seems to free his mind at night (at, at, at night) At, at, at, at, at, at night At, at, at, at, at, at night Hold the phone (what, Van said what) The lonely stoner, Mr. Solo DoMo (what, what) He's on the move can't seem to shake the shade (what, what) Within his dreams he see's the life he made, made The pain is deep from moving the fence(what, what) A silent gummy you won't hear a peep, peep (what, what) The girl he wants don't seem to want him to (what, what) It seems the feelings that she had are through, through 'Cause day and night The lonely stoner seems to free his mind at night He's all alone through the day and night The lonely loner seems to free his mind at night (at, at, at night) Day and night The lonely stoner seems to free his mind at night
Penn +2% after Rosenblatt fires off bull rating, highest PT on the Street Sep. 10, 2020 7:38 AM ET|About: Penn National Gaming, Inc. (PENN)|By: Clark Schultz, SA News Editor Penn National Gaming (NASDAQ:PENN) is on watch after landing a new bull rating just in front of the launch of the Barstool sports app in Pennsylvania and the kickoff of the NFL season tonight in Kansas City. Rosenblatt Securities starts off coverage with a Buy rating on Penn and price target of $80. The thesis from Rosenblatt on Penn grabbing a significant chuck of the sports betting market is similar to other Wall Street firms, but the PT is the highest on the Street. The average PT on Penn has more than doubled since April. For good measure, Rosenblatt assigns a bull case price target of $300 and bear case price target of $300.-? I have to double check that this is not a typo! <-----
SelectQuote skyrockets after strong results, upside full-year forecast Sep. 10, 2020 2:26 AM ET|About: SelectQuote, Inc. (SLQT)
How many planes are needed to deliver a coronavirus vaccine globally? Sep. 10, 2020 4:46 AM ET| Calling it the "largest single transport challenge ever," the International Air Transport Association called on governments to start "careful planning with industry stakeholders" for the large-scale delivery of a coronavirus vaccine. "Just providing a single dose to 7.8B people would fill 8,000 (Boeing) 747 cargo aircraft," according to the air transport body. IFS //// Idea From Stoney-- why not take the entire downed fleet of 787 Max's sitting on tarmacs and use them?
Many moons ago I used SVA. It may have been BIRD Flue. This is a Chinese company so you get with that the headaches. SVA is a real biotech however and they are rushing their own vaccine to trial in China. Healthcare Sinovac COVID-19 vaccine shows positive effect in elderly volunteers Sep. 9, 2020 2:03 PM ET|About: Sinovac Biotech Ltd. (SVA)| Sinovac Biotech Ltd. (SVA) announces positive preliminary results from a Phase 1/2 clinical trial evaluating the safety and immunogenicity of Coronavac, its COVID-19 vaccine candidate, in healthy adults at least 60 years old. 421 volunteers aged between 60 and 89 were recruited. They received two shots of the vaccine 28 days apart. Low, medium and high doses were well-tolerated with no vaccine-related serious adverse events reported. The seroconversion (generation of antibodies) rate and geometric mean titers (GMT) (average level of antibodies in a group) were comparable to those observed in younger adults (aged 18-59) who participated in earlier studies. Specifically, the seroconversion rate in elderly subjects was 98.0% compared to 97.4% in younger adults. GMTs in the medium dose groups were 42.2 and 44.1, respectively. >>>>>>>>>>> I mentioned that we should take a fresh look at INO yesterday... due to the AZN stumble. INO dod have a nice day. Now we can include SVA to the" Little List " Two of the more obscure players in this vaccine race INO & SVA,... One could place a bet and probably hit on one and run from one. (hopefully in time!)
-VoL Alert! Volatility Is An Investors Best Friend. Yesterday I highlighted a company I know nothing of Lovesac. We nominated this company as having the worst name in stocks. What could be worse The Hairy Lovesac Corp? They must of reported earnings because they had a nice DOWN 15% day yesterday.... Seemingly oblivious to this or maybe because of this an analyst hiked a PT today.... Lovesac price target raised to $35 from $33 at Canaccord 07:17 LOVE Canaccord analyst Maria Ripps raised the firm's price target on Lovesac to $35 from $33 and keeps a Buy rating on the shares. The analyst cited its accelerating eCommerce sales as well as strong management execution, unique product, and go-to-market strategy as proof points that the company can take market share in a market that is steadily shifting online. Watch REGN-- They were supposed to be a ' bridge' to the vaccine -- Vaccine may be approved before Regeneron's COVID therapeutic, says Benchmark 07:20 REGN Benchmark analyst Aydin Huseynov said it is becoming "more and more likely" that a COVID-19 vaccine emergency use authorization may come earlier than an emergency authorization for Regeneron's REGN-COV2 therapeutic in a prophylactic setting given rapid vaccine development. In this context, it seems that the commercial opportunity for REGN-COV2 is "somewhat limited" to a hospital setting, said the analyst, who maintains a Hold rating on Regeneron shares given that he is cautious that any positive vaccine news can "negatively correlate" with the stock's performance. >>>>>>>>>>>>>>>>>>>>>>>>>> All very true but there will be 2nd life for REGN. When a vaccine truly stumbles is delayed or when the first group of vaccinated folks begin to grow tails...